There is a paucity of information on long-term outcome of infants who have suffered from meconium aspiration syndrome (MAS) in the neonatal period. We analyzed long-term developmental outcome data of 35 infants who were admitted to the neonatal intensive care unit (NICU) at the University of Illinois Hospital at Chicago (UICMC) with a diagnosis of MAS, and we reviewed the literature pertinent to the subject. The objective of the study was to assess the neurodevelopment status of MAS infants and compare the possible effects of different variables that are known to affect the later developmental outcome. The variables included mode of delivery, APGAR score, cord pH, mode of treatment, and neurological findings during the course of NICU. The infants were enrolled in the developmental followup program (DFUP) after discharge from the nursery for assessment of long-term developmental status and neurodevelopmental outcome. In order to assess the impact of the treatment on long-term outcome and compare our findings with previously published reports, we also reviewed the previously published literature on neurodevelopment outcome of infants treated for MAS (with different modalities) during the last three decades. Total of 35 infants with a diagnosis of MAS admitted to the NICU at UICMC were followed in the DFUP clinic for 3 years during January 1999 to September 2001. The medical records of these infants were reviewed for the mode of delivery, APGAR score, birth weight (BW), gestational age, mode of treatment during the neonatal period, and neurodevelopment status. 19/35 (54%) infants were delivered vaginally, 16/35 (46%) by cesarean section (C-section). All were treated in the delivery room using the standard resuscitation protocol. Following initial resuscitation, all except three required intubation and ventilation for varying duration. One infant required inhaled nitric oxide therapy, and two required extracorporeal membrane oxygenation treatment. Subsequent to discharge, the infants were evaluated in the clinic at 2 months of age, and then every 4 months up to 3 years. The developmental assessment of mental development index (MDI), psychomotor development index (PDI), and behavior rating scale (BRS) were obtained using the Bayley II infant motor scale, and neurodevelopment evaluation was performed using the Amiel-Tison technique. Speech evaluation was performed in infants >18 months using the Rossetti Infant-Toddler language scale. Infants were considered normal when MDI and PDI scores were >85 to 110; mildly delayed when scores were >70 to 84; and severely delayed if the scores were <69. In addition, neurological evaluation also confirmed the disability. The report is based on the final analysis of 29 infants. Data of six infants were not included in the final analysis because of incomplete information. The mean BW of the infants was 3269±671 g; mean gestational age was 39.5±3.1 weeks. The median APGAR score at 1 0 was 4, and at 5 0 was 6. Out of 29, 11 (38%) infants were normal. Out of 29, 2 infants (7%) had cerebral palsy (CP) and 4 (14%) had severe delay at 12 months of age. Out of 29, 2 who were neurologically disabled had PDI <69. Out of 29, 12 (41%) had mild delay in speech. No statistical difference in neurodevelopment was found in infants born vaginally or by C-section. Our findings show poor outcome (CP and global delay) in 21% of infants who suffered MAS, even though the majority of the infants (26/29) responded to conventional ventilator support alone. No difference was found in the outcome of infants between NSVD vs C-section delivery. These findings suggest that infants with the diagnosis of MAS manifest later neurodevelopmental delays, even if they respond well to conventional treatment. This abstract was presented at the Society for
Introduction
Meconium aspiration syndrome (MAS) is a clinical entity that contributes to the high incidence of mortality and morbidity among term pregnancies. 1 The prevalence and mortality in MAS is noted to be steadily decreasing with newer and more efficient modalities of treatment. 1, 2 With steady improvement in survival, the amount of morbidity among the survivors has not changed. There is a great need for follow-up data on the neurodevelopmental outcome of this group of infants. The purpose of this study was to report our findings of neurodevelopmental outcome of infants with the diagnosis of MAS in the neonatal period and review the literature on this supplement.
Methods
We reviewed the medical records of 35 infants with the primary diagnosis of MAS followed in the developmental follow-up program (DFUP) clinic during January 1999 to September 2001 at the University of Illinois Hospital at Chicago (UICMC). Information was collected using the specific diagnostic code for MAS ICD-907 criteria recorded in the obstetric and neonatal intensive care units (NICUs). The criteria for the diagnosis of MAS (ICD-907) include: history of meconium-stained amniotic fluid before delivery, the presence of meconium below the vocal cords at the time of birth in infants >37 weeks of gestation, evidence of respiratory distress, and radiological evidence of aspiration pneumonitis. Many of these infants also developed persistent pulmonary hypertension (PPHN). The medical records of the infants who met the above criteria were selected for the retrospective analysis of perinatal and neonatal events. The study was approved by the internal review board at the University of Illinois at Chicago.
Obstetrical and NICU registry and medical records were reviewed for maternal complications of pregnancy, such as diabetes, hypertension, toxemia, and chorioamnionitis. The presence of meconium-stained amniotic fluid, consistency of meconium, and presence of amnioinfusion were also ascertained. The presence of fetal distress and the mode of delivery were also noted. The infant's condition in the delivery room and any interventions were reviewed. The following data were retrieved from the infants chart: APGAR score at 1 and 5 min, presence of meconium below the vocal cords, method of resuscitation, presence of respiratory distress at birth, the requirement of the use of supplemental oxygen, and ventilator support. The data of cord blood gases and blood gas analysis at the time of admission to the NICU were also noted. The gestational age was determined using fetal ultrasound assessment or Ballard score. Birth weight (BW), length, and head circumference on admission to the NICU were recorded.
Developmental assessment
During the period of 1999 to 2001, 75 infants were diagnosed as having meconium-stained amniotic fluid at the time of delivery. Of these, only 40 infants who developed respiratory distress and met the criteria for MAS were admitted to the NICU. Parents of all infants who were admitted to NICU with a diagnosis of MAS were counseled by the clinic nurse and enrolled for developmental follow-up subsequent to discharge. Only 35 infants attended the follow-up clinic for varying periods of time during the 3-year study period. Among this group, medical records of six infants' did not have complete information; hence, they were not included in the final analysis of this study. The final report includes information on 29 infants.
Developmental evaluation was conducted at 2, 4, 8, 12, 18, 24, 30, and 36 months. Each infant had at least five visits during this period. These evaluations consisted of neurodevelopment assessment by an experienced developmental pediatrician (NB) using the Amiel-Tison neurodevelopment scale and neurological examination. 3 During these visits, complete interim history, immunization status, and physical exams including anthropometric measurements were recorded. Infants were independently evaluated using the Bayley II infant motor developmental scale 4 by a certified pediatric occupational therapist, physical therapist, and the developmental specialist. Infants were scored based on their performance on the Bayley II infant motor scale. Scores of mental development index (MDI), psychomotor development index (PDI), and behavior rating scale (BRS) were also used as criteria for eligibility to enroll in the early intervention program (EIP). Acquisition of language was evaluated by the certified pediatric speech pathologist after the age of 18 months using the Rossetti infant-Toddler language scale. 5 The degree of disability was further classified using one or more of the following criteria. When the PDI <2 s.d. below the mean of p69, the baby's condition was classified as cerebral palsy (CP) with neurological evidence of spasticity. When the MDI <2 s.d. below the mean of p69 for evidence of mental disability, the baby was considered as cognitive delay. Mild delay was considered when the scores of PDI or MDI were X70-84, with clinical evidence of hypotonia (gross motor delay or fine motor) and/or cognitive delay. Speech delay was considered when expressive or receptive function of communication was delayed according to the Rossetti infant-Toddler language scale. 5 Diagnoses of speech delay or hearing impairment were assigned according to the disability. The children with mild and severe delays were enrolled in the statesupported EIP between 4 and 6 months of age. The EIP includes speech therapy, physical or occupational therapy, and developmental therapy as needed.
Analysis and results

Maternal data
Complete maternal data were available in all 29 infants who had complete follow-up data. Total of 16 of these infants were delivered by C-section for fetal distress. 13 infants were delivered by normal spontaneous vaginal delivery. Pregnancy complications included diabetes in 4 patients who were on insulin. Pregnancy induced hypertension in 3, fetal decelaration in 4, chorioamnionitis in 3, premature rupture of membranes in 3 maternal drug use in 6, sickle-cell disease in 4, fever of unknown origin in 3, and presence of prolapsed cord in 3. Umbilical cord pH was available in 16/18 inborn infants and in 2/11 outborn infants. It was noted 8/18 infants had cord pH>7.2 and in two infants cord pH was 6.75 and 7.10. Table 1 shows the perinatal data of infants in the study. Total of 11 outborn infants were transferred to UICMC within 12 h after birth. Method of resuscitation was not available. Mean admission age was 6 h after birth APGAR score ranged from 0 to 7 at 1 min with mean of 4, and at 5 min APGAR score ranged from 4 to 9 with mean of 6.
Neonatal data
We were unable to get the fetal heart rate pattern in many of the infants therefore not included in our data. Thick meconium fluid at the time of delivery in 14 infants and meconium was present below the vocal cord in four infants. Mean gestational age was 39.5 ± 3.1 weeks. All infants were resuscitated in the delivery room, in accordance with the standard NRP protocol. 6 All infants were admitted to the NICU, all required assisted ventilation. Duration of the ventilatory support varied between 2 and 12 days with a mean of 6.4 days. Only one infant was treated with inhaled nitric oxide (INO) and high frequency ventilaton who had severe metabolic acidosis and pulmonary hypertension. Two infants required extracorporeal membrane oxygenation (ECMO) for 12 to 24 days who did not respond to mechanical ventilation.
The neurological findings in the neonatal period showed: fourteen infants developed seizure activity during the first week of life. All had electroencephalography (EEG) recordings. Six of the EEGs demonstrated abnormal foci in the temporal and parietal areas. Thirteen infants had magnetic resonance imaging (MRI) scans during the neonatal course. Eleven infants had normal MRI, and two infants demonstrated cerebral hemorrhage. Table 2 shows developmental outcome at 36 months. In 38% (11/29) of infants, the developmental status at 3 years of age was normal. 41% (12/29) had mild deficits, which consisted of mild hypotonia or mild speech delay. 7% (2/29) had CP. 14% (4/29) had severe global delay. None required oral or gastric tube feeding. All had normal nutritional status. 19/29 infants (65%) were enrolled in the EIP. Other 10 required anticipatory development counseling.
Developmental outcome data
The growth and development of these infants at 3 years were appropriate for age, with the exception of one infant who had suffered from birth asphyxia resulting in CP. Two infants required phenobarbital for control of seizure even at 2 years of age.
Of the 13 infants delivered by C-section, only 5 were normal, 4 had mild delay, and 4 had severe delay. 16 infants were delivered by NSVD: 6/16 (37.5%) were normal, 8/16 (50%) had mild delay, and 2/16 (12.5%) had severe delay.
Neurodevelopmental outcome did not differ whether they were born vaginally or by C-section.
Discussion
MAS is a distinct clinical syndrome that occurs in term infants.
Severe meconium aspiration occurs in one in 500 deliveries: that is, in only 0.2% of all births. 1, 7 Intrauterine fetal distress and fetal asphyxia in utero before birth have been recognized as stimulating and enhancing the intestinal peristalsis of the infant, resulting in relaxation of the anal sphincter and passage of meconium in utero. 8, 9 Previous reports 8,10 have described the pathophysiology of MAS. The hypoxic distress of the fetus and gasping in utero have been speculated as the cause of the meconium aspiration during labor and at birth. Aspiration of thick meconium may occur during the respiratory effort of the first breath. This leads to obstruction of airways, resulting in profound hypoxia. In addition, meconium may lead to chemical pneumonitis, parenchymal lung damage, and inactivation of surfactant. Other complications such as pulmonary hypertension or pulmonary atelectasis with or without pneumothorax have been reported. Severe hypoxia may cause brain injury and hypoxic ischemic encephalopathy.
Since the recognition of these issues, both obstetricians and neonatologists have intensified their efforts to decrease the incidence of MAS using new interventions. The obstetric preventive interventions include amnioinfusion in the presence of thick or thin meconium-stained amniotic fluid 11 before birth of the infant, and suctioning of the oropharynx at the perineum before the delivery of the shoulders. 12, 13 The neonatal interventions include tracheal suctioning at birth in the presence of meconium-stained amniotic fluid 12 to prevent meconium aspiration. Although the survival rate of MAS has greatly improved over the last three decades, 2 the long-term morbidities among survivors have been a major concern. We undertook a study to analyze the long-term outcome of infants treated for MAS in our NICU and compare the same with published reports. However, comparisons of our findings with the published studies are constrained for several reasons. First, the treatment modalities differed. Second, the primary objective of most reports was to study 'the treatment effect' rather than the 'effect of MAS' on long-term outcome. The third issue was that the population included in follow-up studies was the sum total of varied diagnoses (MAS, CDH, PPHN, sepsis, and pneumonia), making it difficult to assess the independent effect of MAS alone on the outcome. Finally, the methods of developmental assessment were not uniform and comparable. We attempt here to summarize the uniformity of evaluation and follow-up methods and findings of the published reports of long-term studies. We try to provide some perspective on our follow-up study, its importance, and its relation to the current literature. Review of the literature during the past 30 years has shown that there were three major strategies of treatment and outcome reports. They included the use of mechanical ventilation in the 1970s, additional ECMO treatment in the 1980s, and INO treatment in the 1990s. The outcome results of the infants treated with these different modalities are summarized in Table 3 and discussed below.
Studies in which the primary treatment of MAS was conventional ventilation alone
In the 1970s, the treatment of MAS infants who developed acute respiratory failure consisted of providing early ventilatory support. 10 The survival was low. The clinical course 10 during the immediate neonatal period and complications of MAS included hypoxic injury of brain, pulmonary atelectasis, air leak syndrome, and other systemic insults.
1 During 1978 to 2000, there were 10 other studies [14] [15] [16] published in this category, and they reported longterm outcome of infants with the primary diagnosis of MAS. In two of these studies, 14, 15 MAS infants were treated with conventional ventilation alone. Marshall et al.
14 in a retrospective study in 1978 identified 13 of the 17 infants (78%) with MAS who survived following conventional ventilator therapy. Follow-up of 11 of the survivors showed that 2/11 had developmental delay (18%). Both had seizures. Brett et al. 15 in 1981 followed 9 of their 11 survivors of hyperventilation using conventional mechanical ventilation therapy. Seven of the survivors had MAS. The range of MDI was 89 to 130. They concluded that hyperventilation was not associated with adverse outcome. Here, the emphasis was on the efficacy of treatment rather than the MAS. Walsh and Suky 16 compared the infants treated with conventional ventilation with the ECMO survivors. 90% of the survivors of the ECMO-treated group had primary diagnosis of MAS. The reported morbidity in the ECMO-treated group was twice that of conventional ventilation treated group (55 vs 28%). The reported high morbidity among the long-time survivors, Macrocephaly developed in 24% of the ECMO group. They also found 4/17(28%) of the conventionally treated group had severe neurodevelopmental disabilities, compared with the 20/38 (26%) of the ECMO-treated group.
Outcome of infants following ECMO treatment in the 1980s
Bartlett et al. 17 used ECMO in the management of infants with MAS who failed to respond to conventional therapy. The rest of the eight studies [18] [19] [20] [21] [22] [23] [24] [25] reported following outcome with ECMO treatment. Four of them [18] [19] [20] 25 showed adverse outcome. Three studies [21] [22] [23] showed that, although MAS infants had higher disabilities compared with the normal infants, they were better than infants with diaphragmatic hernia (CDH) and sepsis. Ikle et al. 24 showed in their study no significant difference in the intelligence quotient (IQ) of children at school age, in the ECMOtreated group, except the children with diagnosis of MAS had lower IQ. These studies indicate that infants with the primary diagnosis of MAS have poor neurodevelopmental outcome. Within the ECMOtreated group, the MAS group had a lower incidence of disability than the CDH and sepsis group, suggesting that the presence of sepsis will increase the neurological insult in comparison to MAS.
The ECMO trials reported long-term outcome results. 16, [26] [27] [28] [29] These studies included both MAS and PPHN infants. However, separation of the MAS group was not possible. Overall, the studies showed improved survival following ECMO without concomitant increase in morbidities. There were a few differences among the studies. Vaucher et al. 26 on the other hand reported higher morbidity in the conventional group compared with the ECMO group (25 vs 6% of CP). They also reported that abnormalities found in neuroimaging predicted later clinical neurodevelopmental abnormalities. The UK Collaborative 27 study showed no concomitant increase in morbidities in the ECMO group. RaisBahrami et al. 28 similarly showed that the neurodevelopmental outcome in the 'near-miss ECMO' group (who were sick enough to be on ECMO but were not) had higher handicaps (25 vs 16%) at follow-up than those treated with ECMO.
Glass et al. 29 is the only report that compared the long-term outcome of MAS infants treated with ECMO with healthy controls. These data showed that MAS infants had significantly higher neurodevelopmental delays compared with controls. Most infants undergoing ECMO were in the MAS group. It follows that MAS is associated with higher adverse neurodevelopmental sequelae than the normal population and that these disabilities did not decrease with different treatment modalities, as demonstrated in most of the studies discussed above.
Blackwell et al. 30 showed that there were no differences in the occurrence of seizures between infants with MAS and cord pH<7.20 and those with cord pH>7.20, suggesting that there was a pre-existing injury or that a nonhypoxic mechanism is involved in infants with severe MAS. Casey et al. 31 showed that pH change from birth to immediate neonatal period predicted neonatal morbidity. Infants whose both cord pH and subsequent 2 h arterial pH were <7.20 had a higher incidence of seizures. Total of 55% of infants in this group had associated meconium aspiration, compared with only 36% in infants who had cord pH>7.20. In our study, only 2/29 (6.9%) had severe neurodevelopment impairment; neither required ECMO treatment. These infants experienced severe intrauterine hypoxia, as noted by their cord pH. 34 He concluded that, overall, INO was effective in treating PPHN in MAS. He observed that all the four studies under review [35] [36] [37] [38] reported significant medical and neurodevelopmental sequelae. Ichiba et al. 39 later reported that the outcome of INO-treated infants depended on their response to treatment. Infants who responded early had zero sequelae, compared with those who responded late, who had 11% disabilities. Rosenberg et al. reported 35 one-year survival of INO-treated infants with severe morbidities. He also reported the outcome of infants who survived the randomized trial of INO treatment with confirmed diagnosis of PPHN. These infants were followed for 1 to 2 years. At 1 year of age, 6/51 (11.8%) were found to have severe neurological disability as measured by a Bayley II MDI or PDI score of <69, abnormal neurological findings, and poor weight gain. He concluded that, regardless of the various postnatal treatment strategies, the predisposing factors and underlying factors leading to MAS are fundamental to the pathogenesis of neurodevelopment handicap among the survivors. The NINOS study 36 reported no difference in the outcome between INO-treated infants of the larger group and the control group of infants at 2 years of age. 6/84 INOtreated infants and 7/87 of the controls had CP. 29.9% of the controls and 34.5% of the INO-treated infants had at least one disability, which was defined as CP. Sensory neural hearing loss was observed in 12% of infants. Lipkin et al. 38 reported higher incidence of neurodevelopment disability (CP): 21 and 19% with sensory neural hearing loss. This largest group of survivors from the INO-treated group was also found to have 20% neurodevelopmental disability in the follow-up. However, the resulting morbidity was much higher than noted in our current group.
All the four reports [35] [36] [37] [38] following the treatment with INO claimed improvement in the survival but identified significant neurodevelopment morbidity among the survivors. The NICHD collaborative reports 36, 40 on infants treated with INO who were followed up at 24 months showed no difference in disabilities between the control and the INO-treated groups. Abbreviations: BPB, broncho pulmonary dysplasia, CLD, chronic lung disease; CP, cerebral palsy; CV, conventional ventilation; ECMO, extracorporeal membrane oxygenation; FSIQ, full scale intelligent quotient; HMD, hyaline membrane disease; INO, inhaled nitric oxide; IQ, intelligence quotient; MAS, meconium aspiration syndrome; MDI, mental development index; PFC, persistant fetal circulation; PIQ, performant intelligent quotient; PPHN, persistent pulmonary hypertension; RDS, respiratory distress syndrome; VIQ, verbal intelligent quotient.
Summary
We report follow-up of 29 MAS infants, almost all of whom were treated only with conventional ventilation. Only one infant was treated with INO, and two other infants required ECMO. The infants were followed up to 3 years of age. The findings of this study showed that, in spite of a milder clinical course of illness, severe delay was noted in 21% of the infants. Our study shows that infants with MAS, in spite of adequate respiratory support, have the potential to develop later neurodevelopment deficits. In our study, we analyzed the importance of cord pH to determine the factors that predispose to eventual morbidity. We were able to identify cord pH<6.9 in two infants who also developed CP. There were no differences in the outcome by mode of delivery. As reviewed above, previous follow-up studies show that although different treatment modalities, improved the survival, did not improve the outcome among MAS infants.
Conclusion
Although various degrees of neurologic abnormalities are found in infants who survived MAS in the neonatal period, establishing the causation of neurological insult has been a difficult problem. The above findings suggest poor outcome in MAS, regardless of the mode of delivery (NSVD vs C-section) or mode of treatment (ECMO vs INO). Most infants are asymptomatic at the time of discharge from the nursery. However, on later follow-up, 10-20% of infants demonstrated developmental disabilities. The findings above suggest that there are yet other unidentified events that occur antecedent to delivery of the infant. The presence of meconium at birth may be simply an associated event. 41 The retrospective descriptive study has limitations because of the limited number of patients available. A multicenter trial involving a large number of cohorts of infants with meconium-stained amniotic fluid as well as MAS is very much needed to better understand the mechanisms of development of neurodevelopmental disabilities in these infants.
